Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bristol Myers Squibb Co (BMY)
Price$61.50Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | $16.39B | $17.62B | $21.24B | $19.48B | $18.81B | $17.71B | $15.62B |
| Gross profit | $34.26B | $34.33B | $34.31B | $36.02B | $36.45B | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | $11.77B | $13.01B | $15.65B | $14.21B | $13.67B | $12.40B | $10.70B |
| Gross margin | 71.08% | 71.08% | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 71.34% | 70.67% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | 69.99% | 68.50% |
| Research & development | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | $3.73B | $3.90B | $3.84B | $3.57B | $3.65B | $3.51B | $3.16B |
| Operating expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | $13.49B | $15.28B | $14.26B | $13.41B | $13.21B | $12.94B | $13.09B |
| Operating income | $9.33B | −$8.38B | $8.44B | $7.71B | $8.10B | −$6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | $2.89B | $2.34B | $6.98B | $6.07B | $5.60B | $4.78B | $2.52B |
| Operating margin | 19.36% | −17.35% | 18.75% | 16.71% | 17.46% | −16.16% | 19.03% | 26.45% | 24.70% | 30.45% | 12.54% | 14.99% | 17.64% | 13.28% | 32.86% | 31.16% | 29.79% | 26.96% | 16.16% |
| EBITDA | $13.34B | $1.22B | $18.20B | $17.99B | $18.78B | $3.51B | $6.72B | $6.61B | $5.92B | $6.30B | $2.45B | $2.85B | $3.65B | $3.02B | $7.61B | $6.68B | $6.07B | $5.34B | $3.06B |
| EBITDA margin | 27.68% | 2.53% | 40.44% | 38.97% | 40.50% | 8.25% | 25.71% | 29.28% | 28.49% | 32.41% | 14.81% | 17.94% | 22.30% | 17.14% | 35.82% | 34.27% | 32.28% | 30.13% | 19.63% |
| Net income | $7.05B | −$8.95B | $8.03B | $6.33B | $6.99B | −$9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | $2.56B | $1.96B | $3.71B | $3.10B | $10.61B | $5.25B | $2.17B |
| Net profit margin | 14.64% | −18.53% | 17.83% | 13.71% | 15.08% | −21.20% | 13.15% | 21.81% | 4.85% | 22.94% | 9.45% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 29.62% | 13.86% |
| Basic EPSper basic share | $3.47 | -$4.41 | $3.88 | $2.97 | $3.15 | -$3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | $1.56 | $1.17 | $2.18 | $1.80 | $5.35 | $2.64 | $1.09 |
| Diluted EPSper diluted share | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 | -$3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | $1.54 | $1.16 | $2.16 | $1.79 | $5.34 | $2.62 | $1.09 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BlackRock, Inc. | 180.38M |
VANGUARD CAPITAL MANAGEMENT LLC | 133.34M |
STATE STREET CORP | 102.41M |
JPMORGAN CHASE & CO | 71.71M |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 67.6M |
GEODE CAPITAL MANAGEMENT, LLC | 56.44M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 46.87M |
NORGES BANK | 36.87M |
BANK OF AMERICA CORP /DE/ | 34.05M |
PRICE T ROWE ASSOCIATES INC /MD/ | 31.71M |
MORGAN STANLEY | 29.01M |
AQR CAPITAL MANAGEMENT LLC | 27.36M |
AMERIPRISE FINANCIAL INC | 26.67M |
PRIMECAP MANAGEMENT CO/CA/ | 24.92M |
NORTHERN TRUST CORP | 24.92M |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 22.84M |
Bank of New York Mellon Corp | 21.82M |
Independent Franchise Partners LLP | 21.79M |
DIMENSIONAL FUND ADVISORS LP | 19.69M |
Legal & General Group Plc | 17.02M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 1, 2026Form 4 | Elkins David VEVP, Chief Financial Officer | SellCommon Stock, $0.10 par value | 4.5K | $62.05 | $278.0K | 159.2K |
| Apr 1, 2026Form 4 | Elkins David VEVP, Chief Financial Officer | SellCommon Stock, $0.10 par value | 25.5K | $61.60 | $1.57M | 163.7K |
| Sep 2, 2025Form 4 | Elkins David VEVP, Chief Financial Officer | SellCommon Stock, $0.10 par value | 56.0K | $47.33 | $2.65M | 167.4K |
| Aug 2, 2025Form 4 | Short Bartie WendyEVP, Corporate Affairs | SellCommon Stock, $0.10 par value | 378 | $44.23 | $16.7K | 5.1K |
| May 9, 2025Form 4 | Hickey BenjaminPresident, RayzeBio Org. | SellCommon Stock, $0.10 par value · indirect | 97.39 | $38.01 | $3.7K | 0 |
Community posts
Bristol Myers reports deeper myeloma responses with iberdomide regimen
Bristol Myers Squibb ($BMY) presented Phase 3 EXCALIBER-RRMM results for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Among 420 evaluable patients, 41.1% achieved a complete response wit ...
Bristol Myers reports sustained two-year Sotyktu responses in psoriatic arthritis
Bristol Myers ($BMY) Squibb presented two-year follow-up from the POETYK PsA-2 extension study of Sotyktu in psoriatic arthritis. Among patients continuously receiving treatment, the ACR20 response rate was 76.2% using observed data and 65. ...
